{"id":250,"date":"2018-01-19T19:11:36","date_gmt":"2018-01-19T18:11:36","guid":{"rendered":"https:\/\/journot-lab.igf.cnrs.fr\/?page_id=250"},"modified":"2022-07-28T22:47:54","modified_gmt":"2022-07-28T20:47:54","slug":"zac1-plagl1","status":"publish","type":"page","link":"https:\/\/journot-lab.igf.cnrs.fr\/index.php\/zac1-plagl1\/","title":{"rendered":"ZAC1\/PLAGL1"},"content":{"rendered":"<p><img loading=\"lazy\" decoding=\"async\" class=\"alignleft wp-image-191 size-full\" src=\"https:\/\/journot-lab.igf.cnrs.fr\/wp-content\/uploads\/2018\/01\/lab2.png\" alt=\"\" width=\"64\" height=\"64\" \/><span style=\"color: #000000;\">We originally cloned murine and human <em>ZAC1<\/em> as a Zinc finger transcription factor that induced\u00a0 Apoptosis and cell Cycle arrest in different cell types (<span style=\"color: #0000ff;\"><a style=\"color: #0000ff;\" href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/9184226\">Spengler et al., EMBO J, 1997<\/a>; <a style=\"color: #0000ff;\" href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/9671765\">Varrault et al., Proc Natl Acad Sci USA, 1998<\/a>; <a style=\"color: #0000ff;\" href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/9927333\">Pagotto et al., Endocrinology, 1999<\/a>; <a style=\"color: #0000ff;\" href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/11313869\">Bilanges et al., Oncogene, 2001<\/a><\/span>). Abdollahi and co-workers independently cloned the rat orthologue they named <em>Lot1<\/em> as its expression was Lost On Tranformation of rat epithelial ovary cells (<a style=\"color: #000000;\" href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/9158001\"><span style=\"color: #0000ff;\">Abdollahi et al., Cancer Res, 1997<\/span><\/a><span style=\"color: #0000ff;\">; <a style=\"color: #0000ff;\" href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/10597250\">Abdollahi et al., Oncogene, 1999<\/a><\/span>). <em>ZAC1<\/em>\/<em>LOT1<\/em> was later found to be part of a 3-gene family of zinc finger proteins that includes <em>PLAG1<\/em>-Pleomorphic adenoma gene 1, <em>PLAGL2<\/em> and <em>ZAC1<\/em>\/<em>LOT1<\/em>\/<em>PLAGL1<\/em>.<\/span><\/p>\n<h3><span style=\"color: #000000;\">Is <em>ZAC1<\/em> the 6q24 tumor suppressor gene ?<\/span><\/h3>\n<p><span style=\"color: #000000;\">Given its functional properties, its silencing during epithelial transformation, and its chromosomal localization on 6q24, a region known to harbor a tumor suppressor gene, <em>ZAC1<\/em> was suggested to be the 6q24 tumor suppressor gene. No inactivating mutation has been identified so far, but loss of <em>ZAC1<\/em> expression was observed in various neoplasms (<em>e.g.<\/em> <a style=\"color: #000000;\" href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/9150364\"><span style=\"color: #0000ff;\">Abdollahi et al., Oncogene, 1997<\/span><\/a><span style=\"color: #0000ff;\">; <a style=\"color: #0000ff;\" href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/9671765\">Varrault et al., Proc Natl Acad Sci USA, 1998<\/a>; <a style=\"color: #0000ff;\" href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/10435621\">Bilanges et al., Oncogene, 1999<\/a>; <a style=\"color: #0000ff;\" href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/11156367\">Pagotto et al., Cancer Res, 2000<\/a>; <a style=\"color: #0000ff;\" href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/12473647\">Abdollahi et al., J Biol Chem, 2003<\/a>; <a style=\"color: #0000ff;\" href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/15751035\">Kamikihara et al., Int J Cancer, 2005<\/a>; <a style=\"color: #0000ff;\" href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/16179495\">Basyuk et al., Mol Cancer Res, 2005<\/a><\/span>). We later showed that constitutive inactivation of <em>Zac1<\/em> in mice did not result in tumor formation (<a style=\"color: #000000;\" href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/17084362\"><span style=\"color: #0000ff;\">Varrault et al., Dev Cell, 2006<\/span><\/a>). Hence, 2 decades after its cloning, it is still not clear whether <em>ZAC1<\/em> is the 6q24 tumor suppressor gene.<\/span><\/p>\n<h3><span style=\"color: #000000;\"><em>ZAC1<\/em> is the TNDM gene<\/span><\/h3>\n<p><span style=\"color: #000000;\">In contrast to loss of <em>ZAC1<\/em> function, gain of <em>ZAC1<\/em> function through overexpression is clearly linked to a pathological condition. The demonstration came from 2 independent lines of investigation; 1) the discovery that <em>ZAC1<\/em> is maternally imprinted (<span style=\"color: #0000ff;\"><a style=\"color: #0000ff;\" href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/10757814\">Piras et al., Mol Cell Biol, 2000<\/a>; <a style=\"color: #0000ff;\" href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/10936046\">Arima et al., Genomics, 2000<\/a><\/span>) , and 2) the hunt for the imprinted TNDM-Transient Neonatal Diabetes Mellitus gene on 6q24 (<span style=\"color: #0000ff;\"><a style=\"color: #0000ff;\" href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/10655556\">Kamiya et al., Hum Mol Genet, 2000<\/a>; <a style=\"color: #0000ff;\" href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/20668833\">Docherty et al., Diabetologia, 2010<\/a><\/span>). In that respect, we elucidated <em>ZAC1<\/em> imprinting mechanism by showing that <em>ZAC1<\/em> is maternally imprinted, paternally expressed through the constitutive methylation of its maternal promoter (<span style=\"color: #0000ff;\"><a style=\"color: #0000ff;\" href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/11297535\">Varrault et al., J Biol Chem, 2001<\/a><\/span>).<\/span><\/p>\n<p><span style=\"color: #000000;\">Neonatal forms of diabetes, although not a major threat for the general population compared to T1D or T2D, offer the opportunity to uncover developmentally important genes. Neonatal diabetes (ND) is a monogenic diabetes that encompasses 2 distinct conditions, Transient (TNDM) and Permanent (PND) forms; both conditions are rare (<a style=\"color: #000000;\" href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/20546293\"><span style=\"color: #0000ff;\">Grulich-Henn et al., Diabet Med, 2010<\/span><\/a><span style=\"color: #0000ff;\">; <a style=\"color: #0000ff;\" href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/21953423\">Iafusco et al., Acta DIabetol, 2012<\/a><\/span>).<\/span><\/p>\n<p><span style=\"color: #000000;\">In PND, insulin secretory failure occurs in the late fetal or early post-natal period and does not go into remission. Genes mutated in PND include <em>KCNJ11<\/em> and <em>ABCC8<\/em>, which encode the sulfonylurea receptor 1 (SUR1) and KIR6.2 subunit, respectively, of the \u03b2-cell ATP-sensitive potassium channel. Alternatively, PND patients display mutations of <em>INS<\/em>, <em>GCK<\/em>, or <em>PDX1<\/em> genes.<\/span><\/p>\n<p><span style=\"color: #000000;\">In TNDM, patients are younger at the diagnosis of diabetes and have lower initial insulin requirements. They are more likely to have intrauterine growth retardation and less likely to develop ketoacidosis than patients with PND. Considerable overlap occurs between the 2 conditions, so that TNDM cannot be distinguished from PND based on clinical features early on (<a style=\"color: #000000;\" href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/24622368\"><span style=\"color: #0000ff;\">Busiah et al., Lancet Diabetes Endocrinol, 2013<\/span><\/a>). At least 85% TNDM patients relapse during adolescence and suffer from permanent diabetes (<span style=\"color: #0000ff;\"><a style=\"color: #0000ff;\" href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/24622368\">Busiah et al., Lancet Diabetes Endocrinol, 2013<\/a><\/span>). About 25% of TNDM patients display mutations in the <em>KCNJ11<\/em> or <em>ABCC8<\/em> genes. The majority of TNDM patients (75%) display an imprinting or cytogenetic defect of the 6q24 chromosomal region (<a style=\"color: #000000;\" href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/12471198\"><span style=\"color: #0000ff;\">Temple &amp; Shield, J Med Genet, 2002<\/span><\/a>). The critical 6q24 TNDM region harbors a maternally imprinted, paternally expressed gene, <em>ZAC1<\/em>\/<em>PLAGL1<\/em>, which is the 6q24 TNDM candidate gene (<span style=\"color: #0000ff;\"><a style=\"color: #0000ff;\" href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/20668833\">Docherty et al., Diabetologia, 2010<\/a><\/span>). 6q24 TNDM patients have two active <em>ZAC1<\/em> alleles as the result of 3 possible mechanisms (Figure 1). How <em>ZAC1<\/em> double dosage alters pancreatic \u03b2-cell development or function is unknown; we plan to work on this question in the near future.<\/span><\/p>\n<table class=\"igf_team\">\n<tbody>\n<tr>\n<td><\/td>\n<td><span style=\"color: #000000;\"><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-full wp-image-507\" src=\"https:\/\/journot-lab.igf.cnrs.fr\/wp-content\/uploads\/2018\/02\/TNDM.jpg\" alt=\"\" width=\"733\" height=\"376\" srcset=\"https:\/\/journot-lab.igf.cnrs.fr\/wp-content\/uploads\/2018\/02\/TNDM.jpg 733w, https:\/\/journot-lab.igf.cnrs.fr\/wp-content\/uploads\/2018\/02\/TNDM-300x154.jpg 300w\" sizes=\"auto, (max-width: 733px) 100vw, 733px\" \/><\/span><\/p>\n<h6><span style=\"color: #000000;\"><strong>Figure 1. Molecular cytogenetics of 6q24 TNDM. <\/strong>In contrast to normal controls, TNDM patients have 2 active <em>ZAC1<\/em> alleles as the result of one of 3 possible mechanisms 1) segmental duplication of paternal 6q24 2) uniparental disomy of the paternal chromosome 6 (pat. UPD 6) 3) hypo-methylation of the maternal 6q24 (epimutation).<\/span><\/h6>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h3><span style=\"color: #000000;\"><img loading=\"lazy\" decoding=\"async\" class=\"size-full wp-image-202 alignleft\" src=\"https:\/\/journot-lab.igf.cnrs.fr\/wp-content\/uploads\/2018\/01\/science8.png\" alt=\"\" width=\"65\" height=\"64\" \/><\/span><\/h3>\n<h3><span style=\"color: #000000;\"><em>Zac1<\/em> target genes<\/span><\/h3>\n<p><span style=\"color: #000000;\">More recently, we aimed at identifying <em>Zac1<\/em> target genes genome wide (<a style=\"color: #000000;\" href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/28985358\"><span style=\"color: #0000ff;\">Varrault et al., Nucleic Acids Res, 2017<\/span><\/a>). We showed that <em>Zac1 <\/em>up-regulation was associated with physiological cell cycle exit that occurred with contact inhibition, growth factor withdrawal, or cell differentiation. To gain insights into <em>Zac1<\/em> mechanism of action, we identified its target genes by combining chromatin immuno-precipitation and genome-wide transcriptomics in transfected cell lines. Zac1-elicited gene regulation correlated with multiple binding to the proximal promoter region through a GC-rich motif. Zac1 target genes included numerous genes involved in signaling, cell adhesion, and extracellular matrix composition, including collagens. Zac1 targets also included 22% of the 409 genes that make up the IGN. Altogether, this work identified Zac1 as a transcription factor that coordinated the regulation of a subset of IGN genes and controlled extracellular matrix composition.<br \/>\n<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>We originally cloned murine and human ZAC1 as a Zinc finger transcription factor that induced\u00a0 Apoptosis and cell Cycle arrest in different cell types (Spengler et al., EMBO J, 1997; Varrault et al., Proc Natl Acad Sci USA, 1998; Pagotto et al., Endocrinology, 1999; Bilanges et al., Oncogene, 2001). Abdollahi and co-workers independently cloned the [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-250","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/journot-lab.igf.cnrs.fr\/index.php\/wp-json\/wp\/v2\/pages\/250","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/journot-lab.igf.cnrs.fr\/index.php\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/journot-lab.igf.cnrs.fr\/index.php\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/journot-lab.igf.cnrs.fr\/index.php\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/journot-lab.igf.cnrs.fr\/index.php\/wp-json\/wp\/v2\/comments?post=250"}],"version-history":[{"count":29,"href":"https:\/\/journot-lab.igf.cnrs.fr\/index.php\/wp-json\/wp\/v2\/pages\/250\/revisions"}],"predecessor-version":[{"id":720,"href":"https:\/\/journot-lab.igf.cnrs.fr\/index.php\/wp-json\/wp\/v2\/pages\/250\/revisions\/720"}],"wp:attachment":[{"href":"https:\/\/journot-lab.igf.cnrs.fr\/index.php\/wp-json\/wp\/v2\/media?parent=250"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}